Literature DB >> 22214546

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.

Franz Buchegger1, Oliver W Press.   

Abstract

Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT) consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy.

Entities:  

Year:  2011        PMID： 22214546      PMCID： PMC3251040          DOI： 10.1186/2191-219X-1-7

Source DB:  PubMed          Journal:  EJNMMI Res            Impact factor:   3.138


  14 in total

1.  Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?

Authors:  Tim Martin Illidge
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

Authors:  Oliver W Press; Joseph M Unger; Rita M Braziel; David G Maloney; Thomas P Miller; Michael Leblanc; Richard I Fisher
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

3.  Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice.

Authors:  C A Vogel; M C Galmiche; F Buchegger
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

4.  Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.

Authors:  Franz Buchegger; Cristian Antonescu; Claudine Helg; Marek Kosinski; John O Prior; Angelika Bischof Delaloye; Oliver W Press; Nicolas Ketterer
Journal:  J Nucl Med       Date:  2011-05-13       Impact factor: 10.057

5.  131I-tositumomab therapy as initial treatment for follicular lymphoma.

Authors:  Mark S Kaminski; Melissa Tuck; Judith Estes; Arne Kolstad; Charles W Ross; Kenneth Zasadny; Denise Regan; Paul Kison; Susan Fisher; Stewart Kroll; Richard L Wahl
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

6.  Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Authors:  Thomas E Witzig; Arturo Molina; Leo I Gordon; Christos Emmanouilides; Russell J Schilder; Ian W Flinn; Mohamed Darif; Roger Macklis; Katie Vo; Gregory A Wiseman
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

7.  Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice.

Authors:  R M Sharkey; K S Weadock; A Natale; L Haywood; R Aninipot; R D Blumenthal; D M Goldenberg
Journal:  J Natl Cancer Inst       Date:  1991-05-01       Impact factor: 13.506

8.  Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.

Authors:  Robert M Sharkey; Habibe Karacay; David M Goldenberg
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

9.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Authors:  Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

10.  Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University.

Authors:  M P Mac Manus; R T Hoppe
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544
View more
  1 in total

Review 1.  Introduction to monoclonal antibodies.

Authors:  Jean-Pierre Mach
Journal:  Cancer Immun       Date:  2012-05-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.